ClinicalTrials.gg

Program

zeprumetostat

Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.

Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Nov 5, 202317 company-led studies, 7 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine166 open or runningphase 3since Nov 5, 2023Jul 10, 2018Apr 2027phase 2 · NCT06368167
Treeline Biosciences11 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 10, 2018.

  1. Sep 24, 2020Phase 1 study in HealthyJiangsu HengRui Medicine · NCT04577885 · 18 enrolled · China
  2. Oct 27, 2020Phase 1 study in Healthy Adult SubjectsJiangsu HengRui Medicine · NCT04627129 · 18 enrolled · China
  3. Sep 9, 2021Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT05049083 · 28 enrolled · China
  4. Oct 20, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05592262 · 20 enrolled · China
  5. Dec 15, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05661591 · 18 enrolled · China
  6. Aug 20, 2023Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT06010680 · 6 enrolled · China
  7. Oct 17, 2023Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT06093945 · 20 enrolled · China
  8. Nov 5, 2023Phase 3 study in RecurrenceJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
  9. Dec 8, 2023Phase 2 study in Lymphoma, T-Cell, PeripheralJiangsu HengRui Medicine · NCT06173999 · 100 planned · China
  10. Apr 11, 2024Phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167 · 105 planned · China
  11. Dec 10, 2024Treeline Biosciences's first study: phase 1 study in LymphomaNew to Treeline BiosciencesTreeline Biosciences · NCT06733441 · 50 enrolled · United States, Canada
  12. Jul 29, 2025Phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901 · 351 planned · China
  13. Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220 · 200 planned · China
  14. Nov 13, 2025Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT07230106 · 218 planned · China

Ahead

  1. Nov 15, 2026Primary completion: phase 1 study in LymphomaTreeline Biosciences · NCT06733441
  2. Apr 2027Primary completion: phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167
  3. Dec 2027Primary completion: phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901
  4. Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220

TargetBeta

EZH2 →read by rule
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule

Other programs on EZH2

ProgramCompanyFurthest phaseStudies
mevrometostatPfizerphase 37
TR115ruletarapeutics-science-incphase 33
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07230106Prostatic Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2028218
NCT07175220Carcinoma, Non-Small-Cell Lung · China2RecruitingJiangsu HengRui MedicineOct 2028200
NCT07102901Stomach Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2027351
NCT06733441Lymphoma · United States, Canada1Active, not recruitingTreeline BiosciencesNov 15, 202650
NCT06368167Lymphoma, Follicular · China2Not yet recruitingJiangsu HengRui MedicineApr 2027105
NCT06173999Lymphoma, T-Cell, Peripheral · China2RecruitingJiangsu HengRui MedicineDec 31, 2025100
NCT06122389Recurrence · China3RecruitingJiangsu HengRui MedicineMay 2026130
NCT06093945Neoplasms · China1CompletedJiangsu HengRui MedicineNov 29, 202320
NCT06010680Lymphoma · China1CompletedJiangsu HengRui MedicineNov 27, 20236
NCT05661591Neoplasms · China1CompletedJiangsu HengRui MedicineMar 31, 202318
NCT05592262Neoplasms · China1CompletedJiangsu HengRui MedicineDec 14, 202220
NCT05049083Lymphoma · China1UNKNOWNJiangsu HengRui MedicineJan 6, 202228
NCT04627129Healthy Adult Subjects · China1CompletedJiangsu HengRui MedicineOct 1, 202018
NCT04577885Healthy · China1CompletedJiangsu HengRui MedicineAug 30, 202018
NCT04335266Healthy Adult Subjects · China1CompletedJiangsu HengRui MedicineSep 9, 201920
NCT03741712Prostatic Neoplasms · China2TerminatedJiangsu HengRui MedicineSep 30, 20199
NCT03603951Recurrence · China1UNKNOWNJiangsu HengRui MedicineFeb 14, 2026272

How it is read

Names in the registry

  • “SHR2554”, 6 entries
  • “TLN-254”, 2 entries
  • “SHR2554 Tablets”, 2 entries
  • “SHR2554 Tablet”, 1 entry
  • “SHR2554; Chidamide analog tablets”, 1 entry

Codes read as this program: SHR2554.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.